Xinyu Fang1, Yan Chen1, Yewei Wang1, Juanjuan Ren1, Chen Zhang2. 1. Schizophrenia Program, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China. 2. Schizophrenia Program, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China. Electronic address: zhangchen645@gmail.com.
Abstract
OBJECTIVES: Depressive symptoms are commonly seen in schizophrenia. Increasing evidence implicates that both SIRT1 and BDNF closely related to the development of depression. So we here aimed to explore the effect of BDNF and SIRT1 on the depressive symptoms, and also explore the risk factors for the depressive symptoms in schizophrenia patients. METHODS: A group of 203 participants (case/controls, 174/29) was recruited in the present work. Significant depression was classified by the CDSS score 7 or above. The psychotic symptoms and cognitive functions in schizophrenia patients were evaluated by PANSS and RBANS respectively. And the plasma concentration of SIRT1 and BDNF were measured in 167 participants (case/controls, 138/29). RESULTS: Compared to healthy subjects, schizophrenia patients exhibited notably lower levels of BDNF (P < 0.05). And we observed that patients with depression displayed a worse psychotic symptom (P < 0.01), a poorer cognitive function(P < 0.05), as well as lower plasma BDNF and SIRT1 levels (Bonferroni corrected P < 0.05) compared to those no depressive patients. And the SIRT1 levels were positively correlated with BDNF levels in the case group (P < 0.001). And the regression analysis showed that negative symptoms and general psychopathology in PANSS, attention and delayed memory in RBANS, BDNF and SIRT1 were independent risk factors for depressive symptoms in schizophrenia. CONCLUSION: Aside from the association with psychotic symptoms, we provided evidence suggesting that low BDNF and SIRT1 concentration value may be responsible for the occurrence of depression in schizophrenic patients.
OBJECTIVES:Depressive symptoms are commonly seen in schizophrenia. Increasing evidence implicates that both SIRT1 and BDNF closely related to the development of depression. So we here aimed to explore the effect of BDNF and SIRT1 on the depressive symptoms, and also explore the risk factors for the depressive symptoms in schizophreniapatients. METHODS: A group of 203 participants (case/controls, 174/29) was recruited in the present work. Significant depression was classified by the CDSS score 7 or above. The psychotic symptoms and cognitive functions in schizophreniapatients were evaluated by PANSS and RBANS respectively. And the plasma concentration of SIRT1 and BDNF were measured in 167 participants (case/controls, 138/29). RESULTS: Compared to healthy subjects, schizophreniapatients exhibited notably lower levels of BDNF (P < 0.05). And we observed that patients with depression displayed a worse psychotic symptom (P < 0.01), a poorer cognitive function(P < 0.05), as well as lower plasma BDNF and SIRT1 levels (Bonferroni corrected P < 0.05) compared to those no depressivepatients. And the SIRT1 levels were positively correlated with BDNF levels in the case group (P < 0.001). And the regression analysis showed that negative symptoms and general psychopathology in PANSS, attention and delayed memory in RBANS, BDNF and SIRT1 were independent risk factors for depressive symptoms in schizophrenia. CONCLUSION: Aside from the association with psychotic symptoms, we provided evidence suggesting that low BDNF and SIRT1 concentration value may be responsible for the occurrence of depression in schizophrenicpatients.
Authors: Natalia Rodríguez; Patricia Gassó; Albert Martínez-Pinteño; Àlex-González Segura; Gisela Mezquida; Lucia Moreno-Izco; Javier González-Peñas; Iñaki Zorrilla; Marta Martin; Roberto Rodriguez-Jimenez; Iluminada Corripio; Salvador Sarró; Angela Ibáñez; Anna Butjosa; Fernando Contreras; Miquel Bioque; Manuel-Jesús Cuesta; Mara Parellada; Ana González-Pinto; Esther Berrocoso; Miquel Bernardo; Sergi Mas Journal: Schizophrenia (Heidelb) Date: 2022-04-27
Authors: Evgeny A Ermakov; Elena M Dmitrieva; Daria A Parshukova; Daria V Kazantseva; Alisa R Vasilieva; Liudmila P Smirnova Journal: Oxid Med Cell Longev Date: 2021-01-23 Impact factor: 6.543
Authors: Rodrigo R Nieto; Andrea Carrasco; Sebastian Corral; Rolando Castillo; Pablo A Gaspar; M Leonor Bustamante; Hernan Silva Journal: Front Psychiatry Date: 2021-06-16 Impact factor: 4.157